Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.
暂无分享,去创建一个
M. Climent | E. Gallardo | A. González del Alba | B. Mellado | E. Esteban | J. Bellmunt | C. Rodríguez-Antona | J. García-Donas | A. Font | D. Castellano | F. Moreno | M. Robledo | L. Leandro-García | M. Morente | J. Puente | S. Hernando | J. Arranz | I. Alemany
[1] C. Rodríguez-Antona,et al. Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma. , 2012, Pharmacogenomics.
[2] R. Figlin,et al. Novel Circulating Proteins, Single Nucleotide Polymorphisms (SNPS), and Molecular Tumor Markers as Potential Biomarkers of Sunitinib Efficacy in Treatment-Naïve Patients (PTS) with Advanced Renal Cell Carcinoma (RCC) , 2012 .
[3] C. Porta,et al. Treatment selection in metastatic renal cell carcinoma: expert consensus , 2012, Nature Reviews Clinical Oncology.
[4] B. Rini,et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib , 2012, Cancer.
[5] M. Climent,et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. , 2011, The Lancet. Oncology.
[6] A. Ganser,et al. Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib , 2010, BMC Cancer.
[7] S. Signoretti,et al. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear‐cell renal cell carcinoma receiving vascular endothelial growth factor‐targeted therapy , 2010, BJU international.
[8] R. Bukowski,et al. Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial , 2010, Clinical Cancer Research.
[9] R. Swann,et al. Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers , 2010, Clinical Cancer Research.
[10] R. Porcher,et al. Soluble Isoforms of Vascular Endothelial Growth Factor Are Predictors of Response to Sunitinib in Metastatic Renal Cell Carcinomas , 2010, PloS one.
[11] L. Gossage,et al. Alterations in VHL as potential biomarkers in renal-cell carcinoma , 2010, Nature Reviews Clinical Oncology.
[12] Gurpreet W. Tang,et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.
[13] I. Melero,et al. Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array , 2009, British Journal of Cancer.
[14] C. Andreadis,et al. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers , 2009, BMC Cancer.
[15] F. Waldman,et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. , 2008, The Journal of urology.
[16] M. Michaelson,et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] R. Motzer,et al. Hypoxia-inducible factor (HIF) 1{alpha} and 2{alpha} levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC) , 2008 .
[18] C. Charbonneau,et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. , 2008, Cancer treatment reviews.
[19] John Smeraglia,et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins , 2007, Journal of Translational Medicine.
[20] S. Richard,et al. Somatic von Hippel-Lindau (VHL) gene analysis and clinical outcome under antiangiogenic treatment in metastatic renal cell carcinoma: preliminary results , 2007, Targeted Oncology.
[21] K. Chew,et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel‐Lindau gene status , 2006, BJU international.
[22] G. Landberg,et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma , 2004, BJU international.
[23] T. Deguchi,et al. Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma. , 2008, Oncology reports.